Faron Pharmaceuticals
0.48 EUR
+0.83 %
5,695 following
Corporate customer
FARON
First North Finland
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Dividend
Investor consensus
+0.83 %
-4.16 %
-75.21 %
-75.75 %
-75.39 %
-81.32 %
-85.23 %
-87.89 %
-85.50 %
Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.
Read moreMarket cap
98.27M EUR
Turnover
435.63K EUR
P/E (adj.) (26e)
-4.69
EV/EBIT (adj.) (26e)
-5.4
P/B (26e)
83.99
EV/S (26e)
25,651.72
Dividend yield-% (26e)
-
Revenue and EBIT-%
Revenue K
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
4.5
2026
General meeting '26
26.8
2026
Interim report Q2'26
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types
Redeye: Faron Pharmaceuticals: CRO selected for phase IIb study
Faron Announces Collaboration with Parexel to Support Phase IIb BEXERA Trial in Treatment-Naïve HR-MDS
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
